Anti-Infective Drugs Market to Reach $66 Billion by 2013, Says Report

The anti-infective drugs market will jump to $66 billion by 2013, according to a recently published report.

Anti-infective drugs include: anti-viral therapeutics, antibiotics, anti-fungal agents and prophylactic treatments such as vaccines. Six infectious diseases — pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS — account for half of all premature deaths worldwide. With a worldwide death toll from infectious diseases exceeding 14 million, anti-infective drugs are vital.

To date, the most successful anti-infective drugs target the human immunodeficiency virus (HIV, the virus that causes AIDS), the herpes virus (HSV-1 and HSV-2), bacterial infections and hepatitis C (HCV). Truvada, Valtrex, Cravit, Floxin, Atripla, Pegasys, Kaletra and Reyataz are among the anti-infective drugs with the highest global sales.

The report, entitled  “Anti-Infective Drugs Markets,” was produced by TriMark Publications.

The “Anti-Infective Drugs Markets” report covers:

• Pneumonia
• Influenza
• Avian Bird Flu
• Sinusitis
• Acute Suppurative Thyroiditis
• Complicated Skin and Skin Structure Infections (cSSSIs)
• Lymphadenitis
• Pharyngotonsillitis
• Vascular Infections
• Pancreatitis
• Urinary Tract Infections (UTIs)
• Viral Encephalitis
• Reye’s Syndrome
• Blood-Borne Infections
• Malaria
• West Nile Virus

The “Anti-Infective Drugs Markets” report examines companies manufacturing anti-infective drugs equipment and supplies in the world. Companies covered include: Abraxis Bioscience, Acambis, Achillion, Adlyfe, Advanced Life Sciences Holdings, Affinium, Akonni Biosystems, Alnylam, APP, Aquapharm Biodiscovery, Arbor Vita, Arpida, Avexa, Basilea, Baxter, Biophage Pharma, CEL-SCI, Cerexa, Combimatrix, Cubist, Daiichi Sankyo, Hospira, Idenix, Incyte, Medivir, Meiji Holdings, MerLion, Mutabilis, Nanobio, Nanosphere, Nanoviricides, Novabay, Obetech, Optimer, Panacos, Paratek, Pharmasset, Pico, Polymedix, Powdermed, Presidio, Progenics, Protez, Rib-X, Ribomed, Targanta, Theravance, Trius, Vertex and X-GEN.

Detailed charts with sales forecasts and marketshare data are included.

More information: TriMark Publications.

Source: Business Wire